DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
CC-223 is an investigational drug.
There have been 5 clinical trials for CC-223. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lymphoma, Large B-Cell, Diffuse, and Lymphoma, B-Cell. The leading clinical trial sponsors are Celgene Corporation and [disabled in preview].
Recent Clinical Trials for CC-223
|Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma||Celgene Corporation||Phase 1|
|CC-223 and Ketoconazole Drug-Drug Interaction Study||Celgene Corporation||Phase 1|
|A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects||Celgene Corporation||Phase 1|